1. Academic Validation
  2. PLOD1 promote proliferation and migration with glycolysis via the Wnt/β-catenin pathway in THCA

PLOD1 promote proliferation and migration with glycolysis via the Wnt/β-catenin pathway in THCA

  • Genomics. 2024 Oct 16;116(6):110943. doi: 10.1016/j.ygeno.2024.110943.
Wei Cong 1 Jingfu Sun 2 Zhanyu Hao 2 Maosong Gong 2 Jianing Liu 3
Affiliations

Affiliations

  • 1 Department of Thyroid Surgery, The Second Hospital of Shandong University, Shandong University, Shandong Province, PR China. Electronic address: 17660081267@163.com.
  • 2 Department of Thyroid Surgery, The Second Hospital of Shandong University, Shandong University, Shandong Province, PR China.
  • 3 Department of Thyroid Surgery, The Second Hospital of Shandong University, Shandong University, Shandong Province, PR China. Electronic address: jianingliu1974@163.com.
Abstract

THCA (Thyroid carcinoma) is the most common endocrine malignancy in the world. The PLOD1 is highly expressed in THCA, but the mechanism is still unclear. It is found that the cell proliferation and migration were inhibited in si-PLOD1 group, and promoted with PLOD1 overexpression. MAZ is the transcription factor of PLOD1. The cell activities induced MAZ were reversed by si-PLOD1. The Glucose uptake, lactate production and ATP/ADP ratio were decreased with si-PLOD1. The glycolysis related proteins GLUT1, HK2, PFKP, PKM2, LDHA and Wnt/β-catenin pathway proteins WNT5A, cyclin D1, β-catenin were inhibited, GSK-3β is increased in si-PLOD1 group. BML-284 could reversed the si-PLOD1 effects on cell activities and Wnt/β-catenin pathway. The tumor xenografts were inhibited in si-PLOD1 group. As a potential therapeutic target, PLOD1 is regulated by MAZ in THCA. PLOD1 depletion could inhibit THCA cell proliferation and metastasis by glycolysis, which is inhibited by Wnt/β-catenin pathway in THCA.

Keywords

Glycolysis; MAZ; PLOD1; Proliferation; Thyroid carcinoma; Wnt/β-catenin pathway.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-19987
    99.95%, Wnt Signaling Activator
    Wnt